Recherche Fr menu ClientConnect
Recherche
Résultats
5 premiers résultats de la recherche Voir tous les résultats Recherche avancée
Recherches les plus fréquentes
Pages les plus visitées
    Référence: 20200063
    Date de publication: 10 décembre 2020

    Promoteur – Intermédiaire Financier

    ATRIVA THERAPEUTICS GMBH

    Lieu

    Description

    Financing the borrower's research and development (R&D) and clinical trials related to its novel antiviral drug ATR-002, which will target influenza and other respiratory viruses, including SARS-CoV-2.

    Objectifs

    The project supports a biotech company to develop a novel antiviral medicinal product for influenza and other respiratory viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The eligible investment plan includes R&D and related expenses.

    Secteur(s)

    • Services - Activités spécialisées, scientifiques et techniques

    Montant BEI envisagé (montant approximatif)

    EUR 24 million

    Coût total (montant approximatif)

    EUR 30 million

    Aspects environnementaux

    The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2014/52/EU amending the EIA Directive 2011/92/EU. Full environmental details will be verified during the appraisal.

    Passation des marchés

    The Promoter is a private company not operating in the utilities sector and not having the status of a contracting authority; thus, the project is not covered by the EU Directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.

    Statut

    Signé - 16/10/2020

    Clause de non-responsabilité

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Mots-clés correspondants

    Allemagne Services